Invitation to "Fallen Angel" Reverse Mergers: An Alternative to the Traditional IPO

An Invitation from Mintz Levin  |  View online  |  Forward this email

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.


Join Us —


"Fallen Angel" Reverse Mergers: An Alternative to the Traditional IPO


  The IPO market in 2016 was abysmal, especially for the life sciences sector. Annual IPO proceeds fell to the lowest level since 2003. The IPO market forecast for 2017 is uncertain.
  Some life sciences companies that went public during the last IPO wave ending in 2015 still have plenty of cash yet they have "hit the wall" clinically, making them "fallen angels".
  In this environment, the "fallen angel" reverse merger has emerged as an attractive way for many promising life sciences companies to raise capital and to go public.


Join the lawyers at Mintz Levin for a panel discussion about fallen angel reverse mergers as an alternative to the traditional IPO, and learn whether this important approach might be right for your company. Our panel of experts will provide the perspectives of the deal lawyer, the private company, the fallen angel, the investor, the investment banker, and the Nasdaq consultant. You will gain insights into the key issues involved in evaluating a fallen angel reverse merger strategy, negotiating a deal, smoothly completing a transaction, and being ready for life as a public company.




Monday, March 6, 2017


3:00 – 3:30 pm | Registration
3:30 – 5:00 pm | Program
5:00 – 6:00 pm | Cocktail Reception


Add to Calendar

Add this date
to your calendar




Mintz Levin, Boston Office – 38A


One Financial Center
Boston, MA 02111


Get Driving Directions

Get driving








Forward Invitation



CLE Credit

Mintz Levin is an approved CLE provider. This seminar is accredited in the following states: California (1.5 general credit) and New York (1.5 credit in the Areas of Professional Practice).




Matt Gardella

Matthew J. Gardella
Member, Mintz Levin


Megan Gates

Megan N. Gates
Co-Chair, Securities & Capital Markets Practice, Mintz Levin


Marc Schneebaum

Marc R. Schneebaum
Senior Vice President and Chief Financial Officer, Madrigal Pharmaceuticals, Inc.


Pete Zorn

Pete Zorn
Chief Corporate Officer and General Counsel, Albireo Pharma, Inc.



Scott Morenstein
Managing Director, CAM Capital


Andrew Weisenfeld

Andrew J. Weisenfeld
Partner, MTS Health Partners



David A. Donohoe, Jr.
Principal, Donohoe Advisory Associates




BostonLondonLos AngelesNew YorkSan DiegoSan FranciscoStamfordWashington

Follow Us LinkedIn Facebook Twitter YouTube

Your e-mail address is never shared with any third parties. For more information, view our Privacy Statement.





Cvent - Web-based Software Solutions